Sanofi SA (SNY) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Cenrifki for treating secondary progressive multiple sclerosis (SPMS) in patients without relapses in the past two years.
A final decision from the agency is expected in the coming months.
The positive opinion is based on data from the HERCULES Phase 3 study in non-relapsing SPMS, supported by findings from the GEMINI 1 and GEMINI 2 Phase 3 studies in relapsing multiple sclerosis.
Sanofi said additional regulatory submissions for Cenrifki are currently under review in multiple countries worldwide.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.